ClinicalTrials.gg
RecruitingNCT05753813Updated Nov 17, 2026

Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome

An Early Phase 1 interventional study of Phexxi in Bacterial Vaginosis and Vulvovaginal Candidiasis, sponsored by Queen's Medical Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Queen's Medical Center · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Nov 17, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 54 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Vaginosis, Bacterial with a site in United States — 8 open to participants now, 8 under way, none of them phase 3. Vaginosis, Bacterial · United States.

Planned enrollment
55th of 69
22 · median 81
Started
2023
with 2 others
Phase 1
12 of 82
1 open now
Registered
69th of 82
by date

Among the 82 studies in Vaginosis, Bacterial with a site in United States, this one is the 55th largest by planned enrollment of the 69 interventional ones that give a count, is one of 3 that started in 2023, is one of 12 in phase 1, and was the 69th registered.

Vaginosis, Bacterial

240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.

Browse Vaginosis, Bacterial studies →

Open to participants now

8 of the 82 studies in Vaginosis, Bacterial with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Vaginosis, Bacterial studies recruiting now, 7 (30%) set no upper age limit and 16 (70%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 54 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Vaginosis, Bacterial with a site in United States, or all of them as a file.
02

Study summary

This project aims to investigate if the contraceptive method, Phexxi, causes changes to the composition of the vaginal microbiome. The investigators hypothesize that regular use of Phexxi will cause increased colonization of lactic acid-producing lactobacilli, which could have positive effects in the way of preventing recurrent episodes of BV and candida infections.

Read the detailed description

This is a single center, prospective trial, which comprises of a pre-post study design that will be looking at the vaginal microbiome makeup of participants before and after a four-week course of Phexxi. The primary outcomes will be an increase in lactic acid-forming lactobacilli, as well as a decrease in patient-reported symptoms of vulvovaginitis.

This study will be based at the Queen's Medical Center (QMC), POB1 Suite 1004. Eligible patients will be approached by participating clinicians (all doctors providing care at the 1004 clinic) to assess interest in study participation.. The principal investigator will review the weekly schedule for the 1004 clinic and alert the attending physicians of patients who may be eligible for the study based on chart review. A HIPAA waiver will be required for this stage of recruitment, as the principal investigator would otherwise not be accessing these patient's charts. The attending physician staffing the 1004 clinic will ask the flagged patients if they are interested in learning about the study and review general study objectives with patients. If the patient is interested in participating, the research associates will approach the patient to more thoroughly screen, then conduct the informed consent process. Informed consent will be collected from every participant prior to the start of the study.

After obtaining informed consent, the research team will review standardized instructions for using the study medication with the patient and the research associate will provide a take-home kit including all of the study materials, including instructions for collecting each swab and for returning the samples. Samples will be self-collected by participants at their home at intervals specified in the study instructions. All materials provided to the patient will be pre-labeled with their study ID, protecting each participant's PHI. No collections will take place in-clinic. These materials include all surveys, patient's diary, and all swab vials. The three collection points are as follows: 1) baseline, prior to starting intervention (see below for recommendations on collecting baseline swab), 2) after completion of the intervention (30 days after baseline collection), and 3) 30 days after completion of the intervention (60 days after baseline collection).

All vaginal swabs must be frozen within 48 hours of collection. As such, the participants will be asked to send their samples within 24 hours in order to give adequate time for delivery to the storage facility and be asked to collect their specimens between Sunday and Thursday so samples can reach the facility during business hours. Freezing will occur at the research site. Each patient's study kit will include a prepaid shipping envelope, which the participant can use to mail or drive their specimen to the research team who will then place it in the freezer until it is ready for analysis.

The first phase of the study will include an assessment and classification of patients' vaginal microbiome prior to receipt of the intervention. To get the best representation of the participant's baseline microbiome, the participant will be asked to collect their baseline swab no sooner than 10 days after menses, as menses-induced changes in the microbiome have been shown to resolve after this time12. For similar reasons, if participants are being treated with an acute course of antibiotics or antifungals at the time of recruitment, they will be asked to wait 10 days after the completion of their medication course before collecting their baseline swab. There will be two additional time points for collection: collection 2) at the end of the 30 day intervention, and collection 3) 30 days after completion of the intervention.

Once received at the research site, samples will be stored in a specimen freezer at -80 degrees F until all specimens are received, at which point they will analyzed using NextGen sequencing, a DNA sequencing technology that will identify the genetic makeup of their specimens. This will be done to sequence the genome of the bacteria of the microbiome, not the patient's genetic material. The first phase of the study will also include a survey, which will collect demographic information from each participant, as well as assess patients' current acceptability of a vaginal gel for prophylactic use, their most bothersome symptoms, and how their quality of life is affected by recurrent vulvovaginitis. The specific information collected from each participant can be found below in Data Analysis. The survey used to measure this will be the Vulvovaginal Symptom Questionnaire (VSQ), which has been validated for the purposes stated above. There will also be an added space in the survey provided for open-ended answers and comments.

Measurement for primary outcomes will be done using two separate methods. In order to assess for the presence of lactic acid-forming organisms before and after the lactic acid gel intervention, NextGen DNA sequencing will be completed on self-collected samples submitted by participants. The analysis of these samples will be performed by Dr. Miller, at an in-house lab run by the UH Maternal Fetal Medicine division. In order to assess for patient-experienced symptoms, survey B will be administered prior to, immediately after, and 30 days after intervention.

In order to measure our secondary outcome, Survey C will be administered at collection points 2 and 3 of the vaginal swabs. This survey is a validated tool to assess for the acceptability, appropriateness, and feasability of an intervention (Acceptability of Intervention Measure, or AIM, Intervention Appropriateness measure, or IAM, and Feasibility of Intervention Measure, or FIM).

The intervention will take place on a rolling basis, as patient participation will have no bearing on other participants. The intervention itself will take place over thirty days. 8 pre-filled vaginal inserters with vaginal gel, will be provided to each of the participants with verbal and written instructions for application. Patients will be instructed to use Phexxi twice per week, on the same days every week. Throughout the 30 days, participants will also be asked to keep a diary of events occurring when they used the product, such as intercourse or menses, as well as record any symptoms or side effects they noticed when using the product. The diary can be sent back with the second specimen vial. Disposal of the product may be done in a regular waste basket.

Approximately 30 days after completion of the intervention, participants will receive an email reminder to collect and send a third collection swab in for analysis. This email will also include the link for the third and final set of surveys.

03

Conditions studied

  • Bacterial Vaginosis
  • Vulvovaginal Candidiasis
04

Who can participate

Ages eligible
18 Years to 54 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-54
  • Female
  • Pre-menopausal
  • Can speak and read in English
  • Displays capacity for
  • Has had 2 or more documented and/or self-reported episodes of symptomatic BV or candida infection in the last year, requiring, over-the-counter or prescription treatment

Exclusion criteria

Exclusion Criteria:

  • Pregnant or trying to become pregnant
  • Using NuvaRing device
  • A past medical history of kidney disease, recurrent UTI, and/or urinary tract abnormalities
  • Current UTI
  • Using Phexxi as a during the collection period of the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Study group

    This is a single-arm study. all participants are assigned to this arm. all study participants will receive Phexxi, the study drug. 8 pre-filled vaginal inserters with vaginal gel, Phexxi, will be provided to each of the participants with verbal and written instructions for application. Patients will be instructed to use Phexxi twice per week, on the same days every week.

    Drug: Phexxi

Interventions

  • DrugPhexxi

    intravaginal gel twice weekly for 4 weeks.

06

What researchers measure

Primary outcomes

  1. To assess participant's baseline vaginal microbiome makeup

    NextGen analysis pre-intervention

    Time frame: Within one week of recruitment, unless menstruating. If this is the case, the participant will be asked to wait 10 days from the cessation of menses in order to allow restoration of baseline vaginal microbiome

  2. To assess if the use of Phexxi causes changes in the vaginal microbiome from baseline after thirty days of use

    NextGen analysis immediately post-intervention

    Time frame: 30 days after baseline vaginal swab collection

  3. To assess if the use of Phexxi causes changes in the vaginal microbiome

    NextGen analysis 30 days post-completion of intervention

    Time frame: 60 days after baseline vaginal swab collection

  4. To assess participant's baseline vulvovaginitis symptoms

    Survey to be completed pre-intervention

    Time frame: On day of recruitment to the study

  5. To assess if the use of Phexxi decreases vulvovaginitis symptoms in study participants

    Survey to be completed immediately post-intervention. This survey is a validated tool to assess for symptoms of vulvovaginitis (Vulvovaginal Symptoms Questionnaire, or VSQ). It employs a binary scoring system, giving 0 points for no and 1 point for yes, with 21 questions which assess vulvovaginitis symptoms.

    Time frame: 30 days after baseline vaginal swab collection

  6. To assess if the use of Phexxi decreases vulvovaginitis symptoms in study participants

    Survey to be completed 30 days post-completion of intervention. This survey is a validated tool to assess for symptoms of vulvovaginitis (Vulvovaginal Symptoms Questionnaire, or VSQ). It employs a binary scoring system, giving 0 points for no and 1 point for yes, with 21 questions which assess vulvovaginitis symptoms.

    Time frame: 60 days after baseline vaginal swab collection

Secondary outcomes

  1. To assess patient satisfaction/acceptability of this intervention as a therapeutic/prophylactic agent for recurrent vulvovaginitis

    Survey at 2 time points: immediately post-intervention, and 30 days post-completion of intervention. This survey is a validated tool to assess for the acceptability, appropriateness, and feasability of an intervention (Acceptability of Intervention Measure, or AIM, Intervention Appropriateness measure, or IAM, and Feasibility of Intervention Measure, or FIM). It lists a number of statements to assess the above measures and asks the participant to circle the ones which apply to them.

    Time frame: 30 and 60 days after baseline swab collection

07

Study locations

1 of 1 sites recruiting
  • Queens Medical Center, 1004 Clinic POB1
    Honolulu, Hawaii 96813, United States
    Recruiting
    • Olivia H Manayan, MD, MPH · Contact8083487859
    • Olivia H Manayan, MD MPH · Principal investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Patient information will be de-identified and connected to a unique Study ID. All identifiable information will be stored in a password protected and encrypted computer in the PI's research office at QMC, which is secured at the 1004 clinic. The signed consent forms will also be stored at the 1004 clinic, in a folder located in a locked office. Only the PI and Dr. Kaneshiro will have access to the identifiable information. Dr. Miller, who will be performing analysis using specimens prelabeled with the study ID, will not have access to participant PHI. If participants opt, in their initial consent, to receive a copy of their vaginal microbiome results, the results will be sent to them via email, using a QMC email address. In order to encrypt this email, the function [encrypted] will be placed in the subject line.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2023 (actual). Primary completion is estimated for Jan 2027, 37 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Oct 2026 → Jan 2027 and completion Dec 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2023
First posted
Mar 3, 2023
StartActual
Dec 15, 2023
Primary completionEst.
Jan 30, 2027was Oct 2026
CompletionEst.
Jan 30, 2027was Dec 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 30, 2026→Jan 30, 2027
Nov 17, 2026
Study completion
Dec 30, 2026→Jan 30, 2027
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Oct 30, 2026→Jan 30, 2027
    Study completion Dec 30, 2026→Jan 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05753813
Lead sponsor
Queen's Medical Center
Collaborators
University of Hawaii Foundation
Responsible party
Olivia Manayan, MD MPH (PGY-2, University of Hawaii Ob/Gyn Residency, Queen's Medical Center) — Principal investigator
First posted
Mar 3, 2023
Start date
Dec 15, 2023
Primary completion
Jan 30, 2027 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Olivia H Manayan, MD, MPH
Contact
omanayan@hawaii.edu
808-348-7859
Olivia Manayan, MD, MPH
principal investigator · University of Hawaii
Bliss Kaneshiro, MD, MPH
principal investigator · Queen's Medical Center
Corrie Miller, DO
principal investigator · University of Hawaii

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion